Abstract:To turn a disease from highly fatal to highly curable is extremely difficult, especially when the disease is a type of cancer. However, we can gain some insight into how this can be done by looking back over the 50-year history of taming acute promyelocytic leukaemia (APL). APL is the M3 type of acute myeloid leukaemia characterized by an accumulation of abnormal promyelocytes in bone marrow, a severe bleeding tendency and the presence of the chromosomal translocation t(15;17) or variants. APL was considered the most fatal type of acute leukaemia five decades ago and the treatment of APL was a nightmare for physicians. Great efforts have been made by scientists worldwide to conquer this disease. The first use of chemotherapy (CT) was unsuccessful due to lack of supportive care and cytotoxic-agent-related exacerbated coagulopathy. The first breakthrough came from the use of anthracyclines which improved the complete remission (CR) rate, though the 5-year overall survival could only be attained in a small proportion of patients. A rational and intriguing hypothesis, to induce differentiation of APL cells rather than killing them, was raised in the 1970s. Laudably, the use of all-trans retinoic acid (ATRA) in treating APL resulted in terminal differentiation of APL cells and a 90-95% CR rate of patients, turning differentiation therapy in cancer treatment from hypothesis to practice. The combination of ATRA with CT further improved the 5-year overall survival. When arsenic trioxide (ATO) was used to treat relapsed APL not only the patients but also the ancient drug were revived. ATO exerts dose-dependent dual effects on APL cells: at low concentration, ATO induces partial differentiation, while at relatively high concentration, it triggers apoptosis. Of note, both ATRA and ATO trigger catabolism of the PML-RAR alpha fusion protein which is the key player in APL leukaernogenesis generated from t(15; 17), targeting the RAR alpha (retinoic acid receptor a) or promyelocytic leukaemia (PML) moieties, respectively. Hence, in treating APL both ATRA and ATO represent paradigms for molecularly targeted therapy. At molecular level, ATRA and ATO synergistically modulate multiple downstream pathways/cascades. Strikingly, a clearance of PML-RARa transcript in an earlier and more thorough manner, and a higher quality remission and survival in newly diagnosed APL are achieved when ATRA is combined with ATO, as compared to either monotherapy, making APL a curable disease. Thus, the story of APL can serve as a model for the development of curative approaches for disease; it suggests that molecularly synergistic targeted therapies are powerful tools in cancer, and dissection of disease pathogenesis or anatomy of the cancer genome is critical in developing molecular target-based therapies.

Synergic Effects of Arsenic Trioxide and Camp During Acute Promyelocytic Leukemia Cell Maturation Subtends a Novel Signaling Cross-Talk

Arsenic trioxide, a therapeutic agent for APL.

[Experimental study of low dose arsenic trioxide in treatment of patients with acute promyelocytic leukemia].

[In Vitro Study of the Effects of Arsenic Trioxide Combined with 8-Cpt-camp on Differentiation Induction in Retinoic Acid Resistant Acute Promyelocytic Leukemia Cells].

Arsenic Trioxide-Induced Apoptosis and Differentiation Are Associated Respectively with Mitochondrial Transmembrane Potential Collapse and Retinoic Acid Signaling Pathways in Acute Promyelocytic Leukemia

Arsenic Trioxide Replacing or Reducing Chemotherapy in Consolidation Therapy for Acute Promyelocytic Leukemia (APL2012 Trial)

Treatment of Acute Promyelocytic Leukemia with ATRA and As2O3: a Model of Molecular Target-Based Cancer Therapy.

Hypoxia-simulating Agents and Selective Stimulation of Arsenic Trioxide-Induced Growth Arrest and Cell Differentiation in Acute Promyelocytic Leukemic Cells.

Treatment of Acute Promyelocytic Leukemia with Arsenic Compounds: in Vitro and in Vivo Studies

Use Of Arsenic Trioxide (As2o3) In The Treatment Of Acute Promyelocytic Leukemia (Apl) .1. As2o3 Exerts Dose-Dependent Dual Effects On Apl Cells

A Model of Molecular Target-Based Cancer Therapy

In Vitro Studies on Cellular and Molecular Mechanisms of Arsenic Trioxide (as2o3) in the Treatment of Acute Promyelocytic Leukemia: As2O3 Induces NB4 Cell Apoptosis with Downregulation of Bcl-2 Expression and Modulation of PML-RAR Alpha/pml Proteins

Synergistic action of all-trans retinoic acid and arsenic in the treatment of acute promyelocytic leukaemialeukemia on transcriptional expression and epigenetic regulation

Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide: Clinical and Basic Studies

Arsenic-induced PML Targeting Onto Nuclear Bodies: Implications for the Treatment of Acute Promyelocytic Leukemia

Arsenic Trioxide-Induced Mitotic Arrest and Apoptosis in Acute Promyelocytic Leukemia Cells

[Therapeutic Effects of Combination of Arsenic Trioxide with Low-Dose All-Trans Retinoic Acid on Induction of Remission Acute Promyeloeytic Leukemia].

Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.

[Can As2O3 Improve the Prognosis of Childhood Acute Promyelocytic Leukemia?--a Single Center Experience].

Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells

Pml/Rar Alpha Fusion Protein Mediates the Unique Sensitivity to Arsenic Cytotoxicity in Acute Promyelocytic Leukemia Cells: Mechanisms Involve the Impairment of Camp Signaling and the Aberrant Regulation of Nadph Oxidase